PDCD1 and hepatocellular carcinoma: In summary, we found that combination therapy (PD-1 inhibitors plus angiogenesis inhibitors) and HBeAg positive are two independent risk factors for HBVr in patients with HBV-related HCC undergoing PD-1 inhibitors and concurrent first-line antivirals.